Recruiting
NA
INTERVENTIONAL
NCT06598839
Immuno-effect of Tα1 for Stage I NSCLC
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).
Interventions
Name:
Thymosin Alpha1
Type:
DRUG
Description:
subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
Primary Outcomes
Measure:
Number of CTCs
TimeFrame:
4 months after sugery
Description:
Number of peripheral blood circulating tumor cells after Tα1 treatment
Trial Information
NCT ID
NCT06598839
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Yousheng Mao
Last Updated
December 15, 2025